Treatment of wet AMD with less than 12 injections of ranibizumab per year;Behandlung der feuchten altersabhängigen Makuladegeneration mit weniger als 12 Ranibizumab-Injektionen pro Jahr

Klinische Monatsblatter fur Augenheilkunde

Volumn 227, Issue 4, 2010, Pages 294-297

  Gerding, H ^a,b  

^a Klinik Pallas   (Switzerland)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Age related macular degeneration; AMD; Anti VEGF; Intravitreal injection; Lucentis; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; HUMAN; LONG TERM CARE; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT DURATION; VISION;

ANTIBODIES, MONOCLONAL; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INCIDENCE; MACULAR DEGENERATION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 77951578559     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245209     Document Type: Article

References (18)

1. Bhatnagar P, Spaide R R., Takahashi B S. et al. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007 27 846-850 (Pubitemid 47479378)
2. Bolz M, Simander C, Ritter M et al. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular AMD. Br J Ophthalmol 2010 94 185-189
3. Boyer D S., Heier J S., Brown D M. et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 116 1731-1739
4. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444 (Pubitemid 44511558)
5. Cohen S Y., Dubois L, Tadayoni R et al. Results of one-years treatment with ranibizumab for exsudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009 148 409-413
6. Dadgostar H, Ventura A ACM, Chung J Y. et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exsudative age-related macular degeneration. Ophthalmology 2009 116 1740-1747
7. th Euretina Congress 2009
8. Frennesson C, Nilsson U L., Peebo B B. et al. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmologica Epub 2009
9. Fung A E., Lalwani G A., Rosenfeld P J. et al. An Optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007 143 566-583
10. Keane P A., Liakopoulos S, Ongchin S C. et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008 49 3115-3120
11. Kloos P, Bernasconi P, Estermann S et al. Fernvisus und Vergrerungsbedarf nach Ranibizumab bei Patienten mit feuchter altersbedingter Makuladegeneration. Klin Monatsbl Augenheilkd 2008 225 385-391 (Pubitemid 352016464)
12. Lalwani G A., Rosenfeld P J., Fund A E. et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009 148 43-58
13. Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 2008 222 321-323
14. Michalova K, Wickremasinghe S S., Tan T H. et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye 2009 23 1633-1640
15. Regillo C D., Brown D M., Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophtalmol 2008 145 239-248
16. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006 355 1419-1431 (Pubitemid 44511557)
17. Rothenbühler S, Waeber D, Brinkmann C K. et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Ophthalmologica 2009 223 383-389
18. Simader C, Bolz M, Ritter I et al. Comparison of treatment effects of ranibizumab on visual acuity, retinal thickness and retinal morphology when administered monthly versus quaterly with different dosing regimens in the EXCITE trial. ARVO 2009 Abstract #351 @arvo.org and presentation 5.5.2009